Signal-averaged P wave duration and the long-term risk of permanent atrial fibrillation

Scandinavian Cardiovascular Journal

Volumn 42, Issue 1, 2008, Pages 31-37

  Dixen, Ulrik ^a,d   Larsen, Mette Vang ^b   Ravn, Lasse ^c   Parner, Jan ^a   Jensen, Gorm B ^b  

^a Mental Health Center Glostrup   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

^d GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Arrhythmia; Atrial fibrillation; P wave; Risk stratification; Signal averaged

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; ECHOCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; GENDER; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; P WAVE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SINUS RHYTHM;

ACTION POTENTIALS; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL FIBRILLATION; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HEART CONDUCTION SYSTEM; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; REGISTRIES; RESEARCH DESIGN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 41549129036     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.1080/14017430701652282     Document Type: Article

References (24)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98:946-52.
2. Friberg J, Buch P, Scharling H, Gadsboll N, Jensen GB. Rising rates of hospital admissions for atrial fibrillation. Epidemiology. 2003;14:666-72.
3. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954-68.
4. Gallagher MM, Camm AJ. Classification of atrial fibrillation. Pacing Clin Electrophysiol. 1997;20:1603-5.
5. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Said SA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40.
6. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.
7. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109:1509-13.
8. MacNeil DJ. The side effect profile of class III antiarrhythmic drugs: Focus on d,l-sotalol. Am J Cardiol. 1997;80:90G-98.
9. Middlekauff HR, Stevenson WG, Saxon LA, Stevenson LW. Amiodarone and torsades de pointes in patients with advanced heart failure. Am J Cardiol. 1995;76:499-502.
10. Guidera SA, Steinberg JS. The signal-averaged P wave duration: A rapid and noninvasive marker of risk of atrial fibrillation. J Am Coll Cardiol. 1993;21:1645-51.
11. Gorenek B, Birdane A, Kudaiberdieva G, Goktekin O, Cavusoglu Y, Unalir A, et al. P wave amplitude and duration may predict immediate recurrence of atrial fibrillation after internal cardioversion. Ann Noninvasive Electrocardiol. 2003;8:215-8.
12. Guo XH, Gallagher MM, Poloniecki J, Yi G, Camm AJ. Prognostic significance of serial P wave signal-averaged electrocardiograms following external electrical cardioversion for persistent atrial fibrillation: A prospective study. Pacing Clin Electrophysiol. 2003;26:299-304.
13. Stafford P. The signal averaged P wave - out of the back room? Eur Heart J. 1999;20:171-3.
14. Dixen U, Joens C, Parner J, Rasmussen V, Pehrson SM, Jensen GB. Prolonged signal-averaged P wave duration after elective cardioversion increases the risk of recurrent atrial fibrillation. Scand Cardiovasc J. 2004;38:147-51.
15. Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, et al. Natriuretic peptides in atrial fibrillation. Cardiology. 2006;108:35-9 (Epub ahead of print).
16. Ravn LS, Hofman-Bang J, Dixen U, Larsen SO, Jensen G, Haunso S, et al. Relation of 97T polymorphism in KCNE5 to risk of atrial fibrillation. Am J Cardiol. 2005;96:405-7.
17. Aytemir K, Aksoyek S, Yildirir A, Ozer N, Oto A. Prediction of atrial fibrillation recurrence after cardioversion by P wave signal-averaged electrocardiography. Int J Cardiol. 1999;70:15-21.
18. Raitt MH, Volgman AS, Zoble RG, Charbonneau L, Padder FA, O'Hara GE, et al. AFFIRM Investigators. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2006;151:390-6.
19. Dixen U, Joens C, Rasmussen BV, Parner J, Jensen GB. Signal-averagedwave durationand the dimensions of the atria. Ann Noninvasive Electrocardiol. 2004;9:309-15.
20. Stabile G, Bertaglia E, Senatore G, De Simone A, Zoppo F, Donnici G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: A prospective, multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J. 2005; (Epub).
21. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolopril reduces the incidence of atrial fibrillation after myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100:376-80.
22. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et-al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24:2090-8.
23. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-9.
24. Stafford PJ, Cooper J, de Bono DP, Vincent R, Garratt CJ. Effect of low dose sotalol on the signal averaged wave in patients with paroxysmal atrial fibrillation. Br Heart J. 1995;74:636-40.